Skip to Content

Melflufen is Safe and Effective in Patients with Alkylator-Refractory Disease

This recent study evaluated the efficacy of melflufen-dex compared to pomalidomide-dex in patients with multiple myeloma who are refractory to alkylators. The trial’s results contributed to the approval of melflufen-dex in Europe for patients who have undergone at least three previous lines of treatment, including those who have not undergone a transplant or did not progress after a transplant within three years.

Fredrik Hellem Schjesvold

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top